A radioimmunoconjugate comprised of the chimeric monoclonal antibody cG250 conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and lableled with the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90 DOTA chimeric monoclonal antibody cG250 binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.
Leave a Comment